Robert Langer Patents & Innovation Profile — PatSnap Eureka
Robert Langer: Patent Portfolio & Innovation Analysis
Robert S. Langer is an Institute Professor at the Massachusetts Institute of Technology who holds over 3,300 patents spanning drug delivery systems, lipid nanoparticles for mRNA and siRNA delivery, controlled-release biomaterials, and tissue engineering — a portfolio that is essentially without parallel among academic inventors in the life sciences. His foundational research on lipid nanoparticle formulations became a critical enabling technology for Moderna, a company he co-founded, and underpins some of the most commercially significant pharmaceutical platforms in existence.
Top Cited Papers by Year
The 2021 LNP for mRNA delivery paper leads with 2,601 citations, reflecting explosive growth in nucleic acid therapeutics.
Robert Langer's Research Impact by the Numbers
With over 1,020 published papers and citation counts in the thousands, Langer's academic output mirrors the depth and reach of his patent activity across nucleic acid delivery, biomaterials, and controlled release.
Citation Counts — Top Papers by Year
The 2021 LNP for mRNA delivery paper (2,601 citations) and the 2009 siRNA review (2,271 citations) are the two most cited works in Langer's documented output.
Research Theme Distribution
Langer's documented high-citation papers cluster into three core themes: nucleic acid delivery, controlled/stimuli-responsive delivery, and biomaterials & tissue engineering.
Robert Langer's Core Areas of Innovation
Langer's portfolio spans five interconnected domains — each representing decades of parallel research publication and patent filing activity at MIT and its partner institutions.
Lipid Nanoparticles & mRNA Delivery
Foundational IPPatents and research in this domain cover the formulation, optimisation, and in vivo delivery of lipid nanoparticle systems for mRNA and siRNA payloads. This work became the enabling platform for Moderna's COVID-19 vaccine and related nucleic acid therapeutics.
- Lipid nanoparticles for mRNA delivery (2021, 2,601 citations)
- Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity (2014)
- Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery (2012)
siRNA & Oligonucleotide Therapeutics
High-citation clusterA major body of Langer's work addresses the barriers to systemic siRNA and oligonucleotide delivery, including endosomal escape, serum stability, and targeted cellular uptake. His 2009 siRNA review (2,271 citations) remains a foundational reference in this field.
- Knocking down barriers: advances in siRNA delivery (2009, 2,271 citations)
- Advances in oligonucleotide drug delivery (2020, 1,367 citations)
- Restoration of tumour-growth suppression via systemic nanoparticle-mediated PTEN mRNA delivery (2018)
Controlled & Stimuli-Responsive Drug Release
Core research themeThis domain covers polymeric, hydrogel, and composite systems engineered to release therapeutic payloads in response to specific stimuli — magnetic fields, pH, light, and mechanical triggers. Work spans from gastrointestinal resident devices to implantable microactuators.
- pH-responsive supramolecular polymer gel as an enteric elastomer for gastric devices (2015)
- Stimuli-responsive microneedle patches (2021)
- Dynamic omnidirectional adhesive microneedle systems for oral macromolecular drug delivery (2022)
Biomaterials & Nanoparticle Engineering
Multi-decade focusPatents and papers in this domain address the design of synthetic and natural biomaterials for therapeutic applications — including polymer microarrays for high-throughput discovery, protein corona characterisation on nanoparticles, and self-assembled hydrogel systems.
- Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles (2017, 612 citations)
- Self-assembled hydrogels utilising polymer–nanoparticle interactions (2015, 513 citations)
- Polymer microarrays for high-throughput biomaterial discovery (2012)
Tissue Engineering & Cell Encapsulation
Regenerative medicineLanger's tissue engineering work encompasses scaffold design, islet cell encapsulation for diabetes treatment, and hepatocyte culture systems. This domain connects directly to commercial cell therapy efforts and regenerative medicine product development.
- Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells (2018, 318 citations)
- Synthetic elastomers for hepatocyte culture (2009)
- Convection-enhanced macroencapsulation device for islet transplantation (2021)
Robert Langer's Most Cited Research Papers
1,020 papers indexed · Langer's citation profile spans nucleic acid delivery, controlled release, biomaterials, and cell encapsulation — with the top five papers alone accumulating over 7,780 citations.
| Title | Year | Citations | Key Affiliations |
|---|---|---|---|
| Lipid nanoparticles for mRNA delivery | 2021 | 2,601 ↑ | MIT, Moderna, Ohio State University |
| Knocking down barriers: advances in siRNA delivery | 2009 | 2,271 ↑ | MIT |
| Advances in oligonucleotide drug delivery | 2020 | 1,367 ↑ | MIT, University of Oxford |
| Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery | 2012 | 931 ↑ | MIT |
| Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles | 2017 | 612 ↑ | MIT, Harvard-MIT HST, Brigham and Women's Hospital, Stanford |
| Self-assembled hydrogels utilising polymer–nanoparticle interactions | 2015 | 513 ↑ | MIT Koch Institute |
| Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity | 2014 | 483 ↑ | MIT, Alnylam Pharmaceuticals |
| A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices | 2015 | 289 ↑ | MIT, Mass General Hospital, Brigham and Women's Hospital |
| Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells | 2018 | 318 ↑ | MIT, Boston Children's Hospital, Harvard University |
| Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA | 2018 | 290 ↑ | MIT Koch Institute, Brigham and Women's Hospital, Harvard Medical School |
Nucleic Acid Delivery Systems
The single most cited cluster of Langer's published work addresses the challenge of delivering RNA and DNA therapeutics in vivo — from the 2009 siRNA review through the 2021 mRNA lipid nanoparticle work. The 2014 degradable lipidoid paper, co-authored with Alnylam Pharmaceuticals, bridges academic research and direct industry application by characterising structure-function relationships across 1,400 lipid variants.
Controlled & Stimuli-Responsive Delivery
A large body of Langer's published work addresses the engineering challenge of controlled release — through polymeric systems, hydrogels, nanoparticles, or responsive materials. Papers cover magnetic-field-triggered release, photoswitchable nanoparticles, stimuli-responsive microneedle patches, and gastrointestinal resident dosage forms including the pH-responsive enteric elastomer (2015) and triggerable tough hydrogels (2017).
Biomaterials & Tissue Engineering
Langer's biomaterials publications address polymer microarrays for high-throughput discovery, localised dexamethasone delivery to reduce foreign body response, synthetic elastomers for hepatocyte culture, and encapsulation strategies for islet cell transplantation in diabetes treatment — connecting directly to commercial cell therapy and regenerative medicine efforts.
Robert Langer's Key Research Collaborators
Institutional Collaboration Frequency
Collaboration Highlights
Langer's collaboration network is characterised by deep industry-academia partnerships — most notably with Moderna (co-founded by Langer), Alnylam Pharmaceuticals, and a global network spanning Harvard Medical School, Brigham and Women's Hospital, Boston Children's Hospital, and the University of Oxford. Many co-authors on his highest-citation papers are also co-inventors on associated MIT patents, reflecting a deliberate parallel publication-and-patenting strategy.
- Moderna, Inc. 2,601 citation paper
- University of Oxford 1,367 citation paper
- Brigham and Women's Hospital / Harvard Medical School 612 citation paper
- Alnylam Pharmaceuticals 483 citation paper
- Boston Children's Hospital / Harvard University 318 citation paper
Robert Langer's International Research & Commercial Footprint
Langer's collaborations and commercial ventures span institutions and companies across North America, Europe, Asia, and beyond — reflecting the global commercial importance of his IP portfolio.
Collaboration Markets
The United States is the dominant hub for Langer's research and commercial activity, anchored at MIT in Cambridge, Massachusetts, with major partners at Harvard Medical School, Brigham and Women's Hospital, and Moderna. International collaborations documented in his highest-citation papers extend to the University of Oxford in the United Kingdom, Soonchunhyang University in South Korea, the Federal University of Goiás in Brazil, Université Laval in Canada, and King Abdulaziz University in Saudi Arabia — reflecting the global reach of nucleic acid delivery research.
Why Robert Langer's Portfolio Matters
Strategic implications for patent attorneys, in-house IP teams, and R&D strategists working in oncology, RNA therapeutics, drug delivery, and biomaterials.
FTO Considerations
Freedom-to-operate considerations are particularly acute in lipid nanoparticle delivery for nucleic acids. The foundational IP in this space traces directly to Langer's laboratory at MIT. Any organisation developing LNP-based mRNA therapeutics, siRNA treatments, or related nucleic acid delivery systems must conduct thorough prior art analysis against this portfolio — which exceeds 3,300 patents — before committing to a development programme. The commercial stakes are exceptionally high: Moderna's mRNA vaccine platform, one of the most valuable pharmaceutical products in history, is built on technology that originated in part from MIT-Langer research.
Prior Art Relevance
Prior art relevance extends beyond direct competitors in nucleic acid delivery. Researchers filing in biomaterials, tissue scaffolding, implantable device coatings, and cell encapsulation for regenerative medicine will find Langer-originating prior art highly relevant. The publication timeline — with high-citation papers dating back to 2009 and beyond — means that researchers cannot assume recency provides freedom from prior art concerns. The 2009 siRNA delivery review (2,271 citations) and the 2012 nucleic acid nanoparticle paper (931 citations) are foundational references that will appear in virtually any novelty search in these technology spaces.
Robert Langer: Patent & Research Profile — Common Questions
Analyse Robert Langer's Full Patent Portfolio in PatSnap Eureka IP
Search 208M+ patents and 1,020+ Langer papers. Map citation networks, identify licensing opportunities, run FTO analysis, and monitor new filings — all in one AI-native platform.
References & Source Data
- 1. Lipid nanoparticles for mRNA delivery (2021) — PatSnap Eureka Literature · MIT, Moderna, Ohio State University · 2,601 citations
- 2. Knocking down barriers: advances in siRNA delivery (2009) — PatSnap Eureka Literature · MIT · 2,271 citations
- 3. Advances in oligonucleotide drug delivery (2020) — PatSnap Eureka Literature · MIT, University of Oxford · 1,367 citations
- 4. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery (2012) — PatSnap Eureka Literature · MIT · 931 citations
- 5. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles (2017) — PatSnap Eureka Literature · MIT, Brigham and Women's Hospital, Stanford · 612 citations
- 6. USPTO Patent Database — www.uspto.gov
- 7. European Patent Office — www.epo.org
- 8. WIPO Patent Database — www.wipo.int/patentscope
PatSnap Eureka searches 208M+ patents and papers to answer instantly.